Table 16

Case series comparing outcomes in clinically diagnosed versus pathologically proven non-small cell lung cancer (NSCLC) treated with Stereotactic Ablative Body Radiotherapy

AuthorNumber of patientsFollow-up periodOutcomePotential confounding factors
Takeda et al26258 CDLC vs 115 pathologically proven NSCLC20.2 Months CDLC (range 6–59) vs 21.2 months NSCLC (range 6–64)3 Year local control 80% vs 87% (p=0.73) and OS 54% vs 57% (p=0.48)Fewer operable tumours in CDLC group
Verstegen et al263382 CDLC vs 209 pathologically proven NSCLCNot supplied3 Year local control 91% vs 90% (p=0.98) and OS 54% vs 55% (p=0.99)Lower FEV1 and smaller tumour size in CDLC group
Haidar et al26423 CDLC vs 32 pathologically proven NSCLC24.2 Months CDLC (range 2–65) vs 25.8 months NSCLC (range 4–53)Local control at last follow-up 91% vs 94% (p=NS) and actuarial 2 year OS 65% vs 64% (p=NS)Smaller tumour size in CDLC group
Stephans et al26533 CDLC vs 61 pathologically proven NSCLC15.3 Months (range 2–48) for whole cohortNo significant difference in OS (p=0.37)—actual rates not suppliedProbably multiple, but patient characteristics not reported by CDLC/NSCLC
  • CDLC, clinically diagnosed lung cancer; FEV1, forced expiratory volume in one second; NSCLC, non-small cell lung cancer; OS, overall survival.